Antithymocyte globulin or similar anti-T cell antibody therapy ? 4 weeks prior to Cycle 1 Day 1
Use of biologic antibody therapy for cGVHD with rituximab, alemtuzumab, or antithymocyte globulin (ATG) within 3 months of starting treatment with abatacept
Alemtuzumab or ATG within 2 weeks of enrollment.
Patients receiving antithymocyte globulin (ATG) or campath within 28 days of infusion
Patients receiving anti-thymocyte globulin (ATG) or Campath within 28 days of infusion
Treatment with steroids or immunosuppressive therapy such as cyclosporine, tacrolimus, anti-thymocyte globulin (ATG) within 6 months of registration
Patients who have received anti-thymocyte globulin (ATG), Campath, or other immunosuppressive T cell monoclonal antibodies within 30 days
The use of serotherapy to prevent GVHD (e.g., antithymocyte globulin) prior to day 3 post-HCT is permitted.
Patients receiving prednisone > 0.1 mg/kg/day or equivalent at time of enrollment, or who have received anti- thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment.
T cell-directed antibody therapy (eg. Alemtuzumab, anti-thymocyte globulin) within 6 months of enrollment
Anti-thymocyte globulin (ATG) within 8 weeks of HSCT admission
Previous therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than 3 months ago \r\n* Note: previous myeloablative autologous transplant is permitted but not required
Patients who have received alemtuzumab or antithymocyte globulin within 8 weeks of the transplant admission; the absence of these therapies in the medical record will serve as documentation that they were not given
Patients receiving prednisone > 0.5 mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment
Patients receiving Anti-thymocyte globulin (ATG), Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of treatment with Viralym-A.
Patients receiving prednisone > 0.5 mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG), donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment
Patients receiving anti-thymocyte globulin (ATG), or Campath within 28 days of CMV reactivation
Patients receiving anti-thymocyte globulin (ATG), Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment
Patients who have received alemtuzumab or ATG within 8 weeks of the transplant admission
Must not have nonmyeloablative conditioning as defined below:\r\n* TBI =< 2 Gy +/- purine analog\r\n* Flu + Cy +/- antithymocyte globulin (ATG)\r\n* Flu + cytarabine (AraC) + idarubicin (Ida)\r\n* Cladribine + AraC\r\n* Total lymphoid irradiation + ATG
Must not receive antithymocyte globulin as part of pre-transplant conditioning regimens
Patients with a history of documented human anti-globulin antibodies.
Patients who have received alemtuzumab within 8 weeks of the transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin and have an anti-thymocyte globulin level of >= 2 ugm/ml
Patients who have undergone an autologous transplant > 12 months prior to allogeneic transplantation and who have not received multi-agent or immunosuppressive chemotherapy within the preceding 3 months must receive anti-thymocyte globulin (ATG) as part of the preparative regimen
Prior treatment with anti-lymphocyte globulin or anti-thymocyte globulin
Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry.
Participant with post-transplant exposure to donor lymphocyte infusion (DLI), or T-cell or IL-2 targeted medication (e.g. anti-thymocyte globulin [ATG], alemtuzumab, basiliximab, denileukin diftitox) within 100 days prior
Anti-thymocyte globulin (ATG) level of >= 2 ugm/ml
T-cell depletion (including ATG or alemtuzumab) is not allowed.
Received anti-thymocyte globulin (ATG) within 6 months of screening
Patients who have received alemtuzumab within 8 weeks of transplant admission, or who have recently received horse or rabbit anti-thymocyte globulin (ATG) and have ATG levels of >= 2 ugm/ml
Treatment of cGVHD with anti-thymocyte globulins (ATG), or campath within 60 days of screening visit unless used for treatment of acute GVHD
Patients receiving (anti-thymocyte globulin) ATG, Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of treatment with Viralym-C
Received antithymocyte globulin (ATG), or Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment
Antithymocyte globulin or similar anti-T cell antibody therapy ? 4 weeks prior to Cycle 1 Day 1
Treatment with antithymocyte globulin within 28 days of planned infusion of virus – specific, antigen selected T cells
Post-transplant exposure to T-cell or IL-2 targeted medication (e.g. anti-thymocyte globulin [ATG], alemtuzumab, basiliximab, denileukin diftitox) within 100 days prior
Patients receiving anti-thymocyte globulin (ATG), or Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment
Anti-thymocyte globulin, alemtuzumab, bortezomib, or post-transplant cyclophosphamide as part of GVHD prophylaxis
Anti-thymocyte globulin as part of the conditioning regimen
Antithymocyte globulin (ATG) as part of the conditioning regimen
Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen.